Recent Updates
Recently added Catalysts

Tulisokibart Form 1

Phase 1

Healthy | Monoclonal antibody | Other |Merck & Company, Inc.|Last Updated: Apr 8, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLED
Total Trials1
Total Enrollment330
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07405177A Study of MK-7240 in Healthy Participants (MK-7240-009)PHASE1 RECRUITING 330 — — Mar 5, 2026Sep 3, 2026Apr 8, 20262 Australia
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Tulisokibart
At designated timepoints up to 14 weeks

Blood samples will be collected to determine the AUC0-inf of tulisokibart.

Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Tulisokibart
At designated timepoints up to 14 weeks

Blood samples will be collected to determine the AUC0-last of tulisokibart.

Maximum Plasma Concentration (Cmax) of Tulisokibart
At designated timepoints up to 14 weeks

Blood samples will be collected to determine the Cmax of tulisokibart.

Secondary Endpoints
Number of Participants Who Experience an Adverse Event (AE)
At designated timepoints up to 14 weeks
Number of Participants Who Discontinue Study Due to an AE
At designated timepoints up to 14 weeks
Time to Maximum Plasma Concentration (Tmax) of Tulisokibart
At designated timepoints up to 14 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Arm 1: Tulisokibart Form 1EXPERIMENTALParticipants will receive tulisokibart form 1.
Arm 2: Tulisokibart Form 2EXPERIMENTALParticipants will receive tulisokibart form 2.
Interventions
NameTypeDescription
Tulisokibart Form 1BIOLOGICALSolution for injection.
Tulisokibart Form 2BIOLOGICALSolution for injection.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria The main inclusion criteria include but are not limited to the following: * Has a body-mass index (BMI) between 18 and 32 kg/m\^2 Exclusion Criteria The main exclusion criteria include but are not limited to the following: * Has a history of more than 1 episode of herpes zost...

Countries:Australia
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07405177primaryCompletionDate: changed
LOWMay 24, 2026NCT07405177studyFirstPostDate: changed